Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/32802
Title: CNS delivery of anti-CD52 antibodies modestly reduces disease severity in an animal model for multiple sclerosis
Authors: BOGIE, Jeroen 
GRAJCHEN, Elien 
WOUTERS, Elien 
BROUX, Bieke 
STINISSEN, Piet 
VAN WIJMEERSCH, Bart 
HENDRIKS, Jerome 
Issue Date: 2020
Publisher: SAGE PUBLICATIONS LTD
Source: THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 11 (Art N° 2040622320947378)
Abstract: Background and aims: Alemtuzumab is a humanized monoclonal antibody that depletes CD52-bearing B and T lymphocytes. Clinical trials defined that systemic administration of alemtuzumab reduces disease severity in the relapsing-remitting phase of multiple sclerosis (MS). However, its efficacy in progressive MS patients is limited, which may reflect the inability of alemtuzumab to cross the reconstituted BBB in these patients. Objective: to study whether central nervous system (CNS) delivery of anti-CD52 antibodies reduces disease severity and the neuroinflammatory burden in the experimental autoimmune encephalomyelitis (EAE) model. Methods: Anti-CD52 antibodies were administered intrathecally during the acute and chronic phases of EAE. Flow cytometry and immunohistochemistry were utilized to define immunological and pathological parameters. Results: We show that subcutaneously administrated anti-CD52 antibodies completely abolish EAE disease severity. CNS delivery of anti-CD52 antibodies during both the acute and chronic phases of EAE moderately reduces disease severity and the neuroinflammatory burden. Our findings further suggest that CNS delivery of anti-CD52 antibodies impacts both the peripheral and CNS immune cell compartments in the EAE model but not in healthy mice. Conclusion: Collectively, our findings highlight the therapeutic potential of CNS delivery of alemtuzumab for the treatment of progressive as well as early MS.
Notes: Hendriks, JJA (corresponding author), Hasselt Univ, Biomed Res Inst, Dept Immunol & Infect, Agoralaan Bldg C, B-3590 Diepenbeek, Belgium.
Jerome.hendriks@uhasselt.be
Other: Hendriks, JJA (corresponding author), Hasselt Univ, Biomed Res Inst, Dept Immunol & Infect, Agoralaan Bldg C, B-3590 Diepenbeek, Belgium. Jerome.hendriks@uhasselt.be
Keywords: alemtuzumab;CD52;experimental autoimmune encephalomyelitis;lymphocytes;multiple sclerosis;neuroinflammation
Document URI: http://hdl.handle.net/1942/32802
ISSN: 2040-6223
e-ISSN: 2040-6231
DOI: 10.1177/2040622320947378
ISI #: WOS:000563499600001
Rights: Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Category: A1
Type: Journal Contribution
Validations: ecoom 2021
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
2040622320947378.pdfPublished version1.53 MBAdobe PDFView/Open
Show full item record

WEB OF SCIENCETM
Citations

1
checked on Mar 21, 2024

Page view(s)

36
checked on Jun 20, 2022

Download(s)

22
checked on Jun 20, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.